ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PVLA vs PRGO // RSI-14 & 200D SMA MOMENTUM

Palvella Therapeutics Inc. (NASDAQ) VS. Perrigo Company plc (NYSE) • 15-METRIC TALLY: PVLA 1 — PRGO 5
▲ RSI-14 & 200D SMA MOMENTUM LEADER: PVLA
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PVLA VS. PRGO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PVLA PRGO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 35.10% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -27.90% -13.60% -14.30 PRGO /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -1.14% 6.58% -7.72 PRGO /fcf-yield <GO>
Operating Margin — -26.40% — TIE /operating-margins <GO>
Net Profit Margin — -33.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — -2.80% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 7.22% -7.22 PRGO /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 PRGO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 63.2 56.7 +6.50 PVLA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.18B $2.21B -$22.4M PRGO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PVLA REV PRGO REV PVLA GROSS % PRGO GROSS % PVLA FCF PRGO FCF
FY 2025 $0 $4.25B — 35.1% -$25.0M $145.1M
FY 2024 $0 $4.37B — 35.3% -$10.8M $244.6M
FY 2023 $42.8M $4.66B — — -$13.7M $405.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PVLA // BETA —
PRGO // BETA —